Table 2.
Significant associations between VCAN, VEGF, MVD and clinicopathological variables
| Low^ (%) | High^ (%) | p value | Odds ratio (95 % CI) | ||
|---|---|---|---|---|---|
| Stromal VCAN expression | |||||
| Resection outcome | R1 | 6 (28.6) | 31 (70.5) | 0.003* | 0.168 (0.053–0.528) |
| R2a/R2b | 15 (71.4) | 13 (29.5) | |||
| T-stage | T1/T2 | 3 (15.0) | 0 (0) | 0.027* | 3.588 (2.396–5.373) |
| T3/T4 | 17 (85.0) | 44 (100) | |||
| MVD, % (SD) | – | 22.4 (7.7) | 34.4 (12.6) | 0.001** | – |
| Epithelial VCAN expression | |||||
| Resection outcome | R1 | 4 (21.1) | 33 (71.7) | <0.001* | 0.105 (0.029–0.376) |
| R2a/R2b | 15 (78.9) | 13 (46.6) | |||
| MVD, % (SD) | – | 22.9 (9.6) | 33.9 (12.4) | 0.007** | – |
| Negative (%) | Not granular (%) | Granular (%) | p value | Odds ratio (95 % CI) | ||
|---|---|---|---|---|---|---|
| VCAN staining pattern | ||||||
| Resection outcome | R1 | 3 (30.0) | 7 (35.0) | 27 (77.1) | 0.001* | – |
| R2a/R2b | 7 (70.0) | 13 (65.0) | 8 (22.9) | |||
| Gender | Male | 4 (40.0) | 3 (15.0) | 18 (51.4) | 0.028* | – |
| Female | 6 (60.0) | 17 (85.0) | 17 (48.6) | |||
* Fisher’s exact test; ** Kruskal–Wallis test
^Low negative and weak expression, high moderate and weak expression